WNT5a/GSK3/β-catenin Axis Modulates FAP Adipogenesis in Musc
2026-05-06
WNT5a/GSK3/β-catenin Axis Modulates FAP Adipogenesis in Muscle
Study Background and Research Question
Skeletal muscle regeneration relies on the orchestrated activity of multiple progenitor populations. Among these, fibro/adipogenic progenitors (FAPs) are mesenchymal cells with dual potential: they transiently support muscle satellite cell (MuSC) activation and differentiation, yet can also differentiate into adipocytes or myofibroblasts, contributing to pathological fat and fibrotic infiltration in muscle diseases such as myopathies (paper). While embryonic pathways like Hedgehog and Notch have been implicated in FAP fate, the contribution of canonical WNT signaling—long recognized for its role in MuSC biology—remained uncharacterized in FAP adipogenic regulation. The central research question posed by Sacco et al. was: does the WNT/GSK3/β-catenin axis modulate FAP adipogenesis, and could this pathway be therapeutically targeted to restrain pathological fat accumulation in skeletal muscle?Key Innovation from the Reference Study
The study’s core innovation is the identification and functional validation of the WNT5a/GSK3/β-catenin axis as a molecular switch governing the adipogenic differentiation potential of FAPs. By combining pharmacological inhibition, high-dimensional cytometry, and transcriptomic profiling, the authors demonstrate that GSK3 inhibition stabilizes β-catenin, represses PPARγ, and effectively blocks FAP adipogenesis both ex vivo and in vivo (paper). Importantly, they show that WNT5a, a ligand abundantly expressed by healthy FAPs but reduced in dystrophic models, acts upstream to maintain β-catenin activity and suppress deleterious adipogenic drift. This mechanistic insight establishes the WNT5a/GSK3/β-catenin axis as a potential therapeutic target in the context of muscle degeneration.Methods and Experimental Design Insights
The authors employed a multi-layered approach integrating:- Pharmacological screening: FAPs were exposed to small molecule modulators of GSK3, particularly LY2090314, to assess effects on adipogenic differentiation ex vivo.
- High-dimensional mass cytometry and single-cell RNA sequencing: These platforms enabled phenotypic and transcriptional profiling of FAP populations, revealing downregulation of CTNNB1 (encoding β-catenin) during adipogenic commitment.
- In vivo models: C57BL/6J (wild-type) and mdx (dystrophic) mice served as sources of FAPs and as models for muscle injury and fatty infiltration. GSK3 inhibition was tested in vivo via glycerol-induced muscle injury.
- Network modeling and public data integration: In silico analysis of single-cell and bulk RNA-seq datasets allowed for the mapping of WNT ligand sources and downstream signaling events within the muscle niche.
Protocol Parameters
- GSK3 inhibitor (LY2090314) | 100 nM | ex vivo FAP differentiation assay | Identified as effective for β-catenin stabilization and adipogenesis blockade | paper
- Mouse model (C57BL/6J, mdx) | 45-day-old to 18-month-old | in vivo fat infiltration study | Models both healthy and dystrophic muscle environments | paper
- Mass cytometry antibody panel | multi-target, validated clones | FAP and MuSC phenotyping | Enables high-resolution mapping of cell state transitions | paper
- RNA-seq platform | single-cell & bulk | transcriptomic profiling of FAPs | Captures dynamic changes upon signaling perturbation | paper
- Naftifine HCl solubility in DMSO | ≥32.4 mg/mL | antifungal assay setup | For researchers exploring sterol biosynthesis inhibition | product_spec
Core Findings and Why They Matter
Key discoveries from the study include:- GSK3 as a gatekeeper of adipogenesis: Pharmacological blockade of GSK3 in FAPs stabilized β-catenin and suppressed PPARγ, a master adipogenic regulator, thus abrogating adipocyte formation (paper).
- WNT5a as an autocrine/paracrine modulator: FAPs are principal producers of WNT ligands, notably WNT5a; loss of WNT5a in dystrophic FAPs correlates with increased adipogenic drift.
- Functional crosstalk with MuSCs: GSK3 inhibition not only limits fat deposition but also enhances the pro-myogenic role of FAPs, promoting MuSC differentiation via follistatin secretion.
- Translational potential: Modulating this axis could restrain pathological fat infiltration in muscle, providing a rationale for future therapeutic exploration in myopathies and related disorders.
Comparison with Existing Internal Articles
Several internal articles contextualize these findings within broader research on cell signaling and antifungal agents. For instance, the article “WNT5a/GSK3/β-catenin Axis Controls FAP Adipogenesis in Muscle” provides a mechanistic summary aligned with Sacco et al., emphasizing the therapeutic potential of signaling modulation in muscle regeneration. Meanwhile, articles such as “Naftifine HCl and the Future of Translational Antifungal” and “Naftifine HCl: Optimized Antifungal Workflows for Mycology Research” highlight the utility of allylamine antifungal agents—like Naftifine HCl—as research tools for dissecting sterol biosynthesis and membrane regulation in eukaryotic cells. While their focus is on antifungal mechanisms, the shared emphasis on targeted enzyme inhibition (e.g., squalene 2,3-epoxidase) and cell fate modulation bridges the conceptual gap between antifungal research and progenitor cell signaling. This cross-domain relevance underscores the utility of chemical biology tools in both infectious disease and regenerative medicine research.Limitations and Transferability
Despite its integrative strengths, the study has certain limitations:- Preclinical focus: While both ex vivo and in vivo mouse models are robust, the direct translatability to human muscle disease remains to be demonstrated (paper).
- Pathway specificity: The complexity of WNT signaling and potential crosstalk with other developmental pathways (e.g., Notch, Hedgehog) could limit the specificity and predictability of therapeutic strategies targeting this axis.
- Pharmacological tools: The study relies on specific GSK3 inhibitors; off-target effects and bioavailability in clinical settings require further investigation.
- Cellular heterogeneity: Single-cell approaches reveal diversity within the FAP compartment; further work is needed to define subpopulation-specific responses.